Description: Clene Nanomedicine Inc., a biopharmaceutical company, develops technology solutions for drug development. The company develops Clean-Surface Nanosuspension, a technology that produces clean-surface nanocrystal medicines. Its technology also provides a platform for a pipeline of new drug candidates with application across a spectrum of diseases with unmet medical needs. The company focuses on demyelinating disorders and oncology. Clene Nanomedicine Inc. was incorporated in 2012 and is based in Salt Lake City, Utah.
Home Page: clene.com
CLNN Technical Analysis
6550 South Millrock Drive
Salt Lake City,
UT
84121
United States
Phone:
801 676 9695
Officers
| Name | Title |
|---|---|
| Mr. Robert Etherington MBA | CEO, Pres & Director |
| Mr. Mark G. Mortenson | Co-Founder & Chief Science Officer |
| Dr. Robert Glanzman M.D. | Chief Medical Officer |
| Mr. Morgan R. Brown CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Mr. Jerry Miraglia J.D. | Gen. Counsel & Corp. Sec. |
| Mr. Michael T. Hotchkin | Chief Devel. Officer |
| Ms. Mary Anne Mcneil | Head of HR |
| Dr. Tae Heum Jeong D. Mgt. | Consultant |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 3.5862 |
| Price-to-Book MRQ: | 108.1979 |
| Price-to-Sales TTM: | 187.0781 |
| IPO Date: | 2020-12-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 95 |